{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:25:19Z","timestamp":1783031119759,"version":"3.54.6"},"reference-count":43,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej12-0094","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T10:14:17Z","timestamp":1347704057000},"page":"15-28","source":"Crossref","is-referenced-by-count":24,"title":["Liraglutide prevents diabetes progression in prediabetic OLETF rats"],"prefix":"10.1507","volume":"60","author":[{"given":"Nanjing","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"},{"name":"Department of Cadre Sanitarian, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A<i> et al. <\/i>(2003) Follow-up report on the diagnosis of diabetes mellitus. <i>Diabetes Care<\/i> 26(11):3160-3167."},{"key":"2","unstructured":"2. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. <i>Diabetes Care<\/i> 29(6):1263-1268."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q<i> et al.<\/i> (2010) Prevalence of diabetes among men and women in China. <i>N Engl J Med<\/i> 362(12):1090-1101.","DOI":"10.1056\/NEJMoa0908292"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1038\/414782a"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1392"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM<i> et al.<\/i> (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). <i>Circulation<\/i> 116(2):151-157.","DOI":"10.1161\/CIRCULATIONAHA.106.685628"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-11-16"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2328"},{"key":"9","unstructured":"9. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB<i> et al.<\/i> (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. <i>Diabetes Care<\/i> 20(4):537-544."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M<i> et al.<\/i> (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. <i>N Engl J Med<\/i> 344(18):1343-1350.","DOI":"10.1056\/NEJM200105033441801"},{"key":"11","unstructured":"11. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. <i>Lancet<\/i> 374(9702):1677-1686."},{"key":"12","unstructured":"12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. <i>N Engl J Med<\/i> 346(6):393-403."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. <i>Diabetes<\/i> 53(3):654-662.","DOI":"10.2337\/diabetes.53.3.654"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1355"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. <i>Lancet<\/i> 373(9662):473-481.","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1203"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet<\/i> 374(9701):1606-1616.","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2011.158"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1564"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Appleton DJ, Rand JS, Sunvold GD (2005) Basal plasma insulin and homeostasis model assessment (HOMA) are indicators of insulin sensitivity in cats. <i>J Feline Med Surg<\/i> 7(3):183-193.","DOI":"10.1016\/j.jfms.2004.12.002"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"23","unstructured":"23. Wolever TM, Jenkins DJ (1986) The use of the glycemic index in predicting the blood glucose response to mixed meals. <i>Am J Clin Nutr<\/i> 43(1):167-172."},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(93)90009-D"},{"key":"25","unstructured":"25. Services USDoHaH, Administration FaD (2005) Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http:\/\/fdadrugs.legalview.com\/legal-issue\/allay\/fda-alerts\/guidance-for-industry-estimating-the-maximum-safe-starting-dose-in-ini\/449452\/."},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(94)90269-0"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00392.x"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.41.11.1422"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1086\/381717"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.03.010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG<i> et al.<\/i> (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. <i>Int J Obes (Lond)<\/i> 30(9):1332-1340.","DOI":"10.1038\/sj.ijo.0803284"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705397"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db\/db mice. <i>Diabetologia<\/i> 45(9):1263-1273.","DOI":"10.1007\/s00125-002-0828-3"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.3.327"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1131"},{"key":"36","unstructured":"36. Hasnan J, Yusof MI, Damitri TD, Faridah AR, Adenan AS, Norbaini TH (2010) Relationship between apoptotic markers (Bax and Bcl-2) and biochemical markers in type 2 diabetes mellitus. <i>Singapore Med J<\/i> 51(1):50-55."},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.46.11.1718"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. <i>Diabetes<\/i> 56(1):8-15.","DOI":"10.2337\/db06-0565"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1831-8"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S (2008) Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. <i>Int J Clin Pharmacol Ther<\/i> 46(6):273-279.","DOI":"10.5414\/CPP46273"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.10.2929"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/1\/60_EJ12-0094\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:30:38Z","timestamp":1618295438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/1\/60_EJ12-0094\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0094","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}